세계의 mRNA 백신 시장(2025-2030년) : 기술 유형별, 투여 경로별, 제조 공정별, 백신 분류별, 용도 분야별, 최종 사용자별, 유통 채널별 예측

The mRNA Vaccines Market was valued at USD 9.32 billion in 2024 and is projected to grow to USD 10.40 billion in 2025, with a CAGR of 11.86%, reaching USD 18.28 billion by 2030.

mRNA vaccines have emerged as a groundbreaking force within modern healthcare. This innovative therapeutic category has rapidly transitioned from experimental technology to the forefront of global immunization efforts, especially in recent years. The journey of mRNA vaccines is characterized by decades of rigorous research that has effectively translated laboratory breakthroughs into life-saving clinical applications. Their ability to elicit robust immune responses combined with a streamlined development timeline underscores their value in combating both emergent pathogens and chronic diseases.

The advent of mRNA vaccine technology not only redefines traditional vaccine platforms but also introduces a level of flexibility in design and manufacturing. This evolution has opened doors to personalized medical approaches, increasing the potential to address a wider array of infectious diseases, genetic disorders, and even oncological challenges. By leveraging synthetic mRNA sequences, these vaccines pave the way for quicker adaptations when new variants or novel pathogens arise. The scientific community and industry leaders are now witnessing the confluence of novel biochemical insights and practical clinical applications in a field that is transforming global public health dynamics.

In this comprehensive review, we delve into the fundamental aspects and strategic implications of the mRNA vaccine market. The discussion will explore the profound technological innovations, critical market segmentations, and regional as well as corporate trends that are setting the stage for future healthcare developments. As decision-makers navigate an increasingly competitive and fast-paced environment, understanding these dimensions is key to leveraging the full potential of mRNA vaccine technology.

Transformative Shifts Redefining the mRNA Vaccine Ecosystem

The landscape of mRNA vaccines has experienced transformative shifts driven by scientific innovation, regulatory evolution, and a heightened sense of urgency within the global health arena. Recent breakthroughs in nucleoside modification and the refinement of lipid nanoparticle delivery systems have dramatically improved the safety and efficacy of mRNA platforms. These advancements have not only accelerated the pathway from discovery to market but also redefined the competitive environment in the pharmaceutical industry.

Clear regulatory endorsements and government initiatives have further bolstered confidence in these novel platforms, leading to a surge in both public and private investment. As nations prioritize preparedness against future pandemics, the scalable and adaptive nature of mRNA vaccines becomes an attractive proposition. This dynamic is fostering collaboration among academia, industry, and regulatory bodies, laying the groundwork for a robust ecosystem where innovative therapies can quickly respond to emergent global health threats.

This section explores the multiple layers of change that have reoriented traditional vaccine strategies. Emphasis is placed on how rapid prototyping capabilities, digital integration in clinical trials, and enhanced manufacturing efficiencies are collectively steering the market. These shifts are a testament to the sector's resilience and its ability to integrate advanced technologies to meet evolving global health demands.

Key Segmentation Insights Shaping Industry Trends

A nuanced understanding of the mRNA vaccine market is evident when one examines the varied segmentation criteria that frame industry trends. The analysis reveals that technology-oriented segmentation is pivotal, where the market is examined through platforms such as lipid nanoparticle (LNP) systems, naked mRNA technologies, nucleoside-modified mRNA approaches, and self-amplifying mRNA platforms. Specifically, the category of naked mRNA technologies delves deeper into the specialized use of peptide-based carriers and polymeric nanoparticles, underscoring a commitment to both efficiency and targeted delivery.

Additionally, the route of administration provides critical insights into market dynamics. The development and differentiation among inhalable mRNA vaccines, injectable formulations, and oral delivery systems highlight the evolving preferences for patient-centric treatments and the drive towards non-invasive vaccination protocols. Manufacturing processes also contribute significantly to the segmentation strategy, with studies focusing on the dichotomy between cell-free synthesis and in vitro transcription methods, each presenting distinct advantages in terms of scalability and cost-effectiveness.

Vaccine classification further refines market perspectives by distinguishing between preventive and therapeutic vaccines. When viewed through the lens of application areas, the market spans a diverse range of therapeutic needs including cardiovascular disorders, genetic diseases-with in-depth explorations into cystic fibrosis treatments and innovative approaches towards sickle cell disease-and comprehensive strategies against infectious diseases like COVID-19 and influenza; oncology remains an equally promising focus. Furthermore, end-user segmentation elaborates on the contributions of biotechnology firms, contract research organizations, pharmaceutical companies, and research institutes. Lastly, the distribution channel segmentation, examining the roles of both hospital pharmacies and retail pharmacies, adds another layer of insight in understanding how these vaccines reach the end consumer.

Based on Technology Type, market is studied across Lipid Nanoparticle (LNP) Platforms, Naked mRNA Technologies, Nucleoside-Modified mRNA Technologies, and Self-Amplifying mRNA Platforms. The Naked mRNA Technologies is further studied across Peptide-Based Carriers and Polymeric Nanoparticles.

Based on Route of Administration, market is studied across Inhalable mRNA Vaccines, Injectable mRNA Vaccines, and Oral Delivery System.

Based on Manufacturing Process, market is studied across Cell-Free Synthesis and In Vitro Transcription.

Based on Vaccine Classification, market is studied across Preventive Vaccines and Therapeutic Vaccines.

Based on Application Areas, market is studied across Cardiovascular Disorders, Genetic Disorders, Infectious Diseases, and Oncology. The Genetic Disorders is further studied across Cystic Fibrosis Treatments and Sickle Cell Disease mRNA Approaches. The Infectious Diseases is further studied across COVID-19 Vaccines and Influenza mRNA Vaccines.

Based on End-User, market is studied across Biotechnology Firms, Contract Research Organizations, Pharmaceutical Companies, and Research Institutes.

Based on Distribution Channel, market is studied across Hospital Pharmacies and Retail Pharmacies.

Key Regional Dynamics Impacting Market Growth

Regional insights play a crucial role in understanding the geographical influences on the mRNA vaccine market. In the Americas, the landscape is characterized by strong research foundations and a robust network of partnerships, setting the stage for iterative innovation and dynamic market expansions. The mature healthcare infrastructure supports rapid adoption of mRNA vaccine solutions, ensuring that advancements translate effectively into public health outcomes.

The region encompassing Europe, the Middle East, and Africa is marked by a blend of sophisticated regulatory frameworks and dynamic market reforms. This diversity presents unique challenges and opportunities that stimulate investment in localized manufacturing and tailored vaccine formulations. Collaborations between academic institutions and industry stakeholders are particularly significant here, as they foster environments conducive to innovation and strategic market penetration.

In Asia-Pacific, rapid economic growth combined with increasing healthcare investments is catalyzing the adoption of advanced therapeutic solutions. The region demonstrates both flexibility in digital integration and a forward-thinking approach towards novel drug development. The strong emphasis on clinical research and expedited pathways for regulatory approvals is contributing to an ecosystem that is both agile and receptive to transformative therapies. Together, these regional dynamics illustrate a global market where local advancements fuel worldwide progress in mRNA vaccine technology.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Market Movers: Key Company Insights Driving Innovation

The competitive landscape of the mRNA vaccine market is shaped by a consortium of influential companies that are driving both innovation and strategic collaborations. Leading industry players such as Acuitas Therapeutics Inc. and Alnylam Pharmaceuticals, Inc. are at the cutting edge of vaccine delivery system advancements, while Arcturus Therapeutics Holdings Inc. continues to push boundaries with self-amplifying mRNA platforms. AstraZeneca PLC and Bavarian Nordic AS bring substantial resources to the table, ensuring that large-scale production and rapid distribution are seamlessly integrated into market strategies.

Companies like BioNTech SE and CureVac N.V. have significantly advanced the field through pioneering research and agile clinical development pathways. Chongqing Zhifei Biological Products Co.,Ltd. marks another key contributor by leveraging regional expertise to customize vaccine solutions for emerging markets. Furthermore, established pharmaceutical giants including Daiichi Sankyo Company, Limited, Eli Lilly and Company, Ethris GmbH, and GlaxoSmithKline PLC have expanded their interest in mRNA technology, integrating it within broader drug portfolios to respond to a spectrum of therapeutic needs.

Innovators such as Inovio Pharmaceuticals, Inc. and Johnson & Johnson Services, Inc. are complementing these efforts by focusing on fine-tuning delivery mechanisms and clinical efficacy. Meanwhile, Merck & Co., Inc. and Moderna Inc. have cemented their positions as trailblazers with substantial R&D investments and global partnerships. Not to be overlooked, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, and Sanofi S.A. continue to significantly influence market direction through strategic mergers and extensive clinical trials. Companies like Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., and Vertex Pharmaceuticals Incorporated are also pivotal, contributing diversified expertise that enriches the competitive landscape and fosters a spirit of relentless innovation.

The report delves into recent significant developments in the mRNA Vaccines Market, highlighting leading vendors and their innovative profiles. These include Acuitas Therapeutics Inc., Alnylam Pharmaceuticals, Inc., Arcturus Therapeutics Holdings Inc., AstraZeneca PLC, Bavarian Nordic AS, BioNTech SE, Chongqing Zhifei Biological Products Co.,Ltd., CureVac N.V., Daiichi Sankyo Company, Limited, Eli Lilly and Company, Ethris GmbH, GlaxoSmithKline PLC, Inovio Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Moderna Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., and Vertex Pharmaceuticals Incorporated. Strategic Recommendations for Industry Stakeholders

Industry stakeholders are encouraged to foster cross-disciplinary collaborations aimed at accelerating technological maturation and expanding market reach. Investment in research and development should be prioritized, with a keen focus on optimizing delivery systems and enhancing the scalability of manufacturing processes. Stakeholders must also adopt data-driven decision-making frameworks that leverage real-time analytics to forecast market trends and adapt to shifting regulatory environments.

A proactive approach in forming strategic alliances with academic research centers and technology innovators can create synergies that drive both clinical success and market penetration. Emphasis on embracing digital transformation, particularly in clinical trial management and patient engagement strategies, is essential for maintaining competitive advantage. By positioning themselves at the nexus of innovation and patient care, industry leaders can ensure their strategies remain both flexible and forward-thinking in an era marked by rapid change.

Conclusion: Reflecting on the mRNA Vaccine Market's Future Prospects

In summary, the mRNA vaccine market is positioned at a pivotal juncture, where technological breakthroughs and strategic global collaborations are converging to redefine healthcare solutions. The evolution from traditional vaccine platforms to advanced mRNA technologies illustrates a market driven by innovation, adaptability, and a relentless pursuit of precision medicine.

The synthesis of diverse segmentation insights not only unveils detailed market nuances but also highlights the critical role that regional dynamics and key corporate players play in shaping the industry. As the market continues to expand, the alignment of technological innovation with regulatory and commercial strategies will be instrumental in determining long-term success and global impact.

Ultimately, the future of mRNA vaccines is bright, with extensive opportunities emerging for growth, enhanced public health outcomes, and the democratization of advanced therapeutic solutions across diverse populations.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of infectious diseases and emerging viral outbreaks spur demand for mRNA vaccines
    • 5.1.1.2. Expansion of mRNA vaccine in animal health sectors is set to market potential
    • 5.1.1.3. Public and governmental support for pandemic preparedness pushes forward mRNA vaccine initiatives
  • 5.1.2. Restraints
    • 5.1.2.1. Public skepticism towards new vaccine technologies, by misinformation, could impede uptake.
  • 5.1.3. Opportunities
    • 5.1.3.1. Developing educational campaigns and public-private partnerships to promote mRNA vaccine benefits and safety
    • 5.1.3.2. Governmental and private funding to advance mRNA vaccine research and development
  • 5.1.4. Challenges
    • 5.1.4.1. Understanding the complex regulatory frameworks for mRNA vaccine approvals
• 5.2. Market Segmentation Analysis
  • 5.2.1. Technology Type: Growing use of lipid nanoparticle platforms for their ability to deliver mRNA into cells effectively
  • 5.2.2. Distribution Channel: Adoption of hospital pharmacies for storing and timely administering mRNA vaccines
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. mRNA Vaccines Market, by Technology Type

• 6.1. Introduction
• 6.2. Lipid Nanoparticle (LNP) Platforms
• 6.3. Naked mRNA Technologies
  • 6.3.1. Peptide-Based Carriers
  • 6.3.2. Polymeric Nanoparticles
• 6.4. Nucleoside-Modified mRNA Technologies
• 6.5. Self-Amplifying mRNA Platforms

7. mRNA Vaccines Market, by Route of Administration

• 7.1. Introduction
• 7.2. Inhalable mRNA Vaccines
• 7.3. Injectable mRNA Vaccines
• 7.4. Oral Delivery System

8. mRNA Vaccines Market, by Manufacturing Process

• 8.1. Introduction
• 8.2. Cell-Free Synthesis
• 8.3. In Vitro Transcription

9. mRNA Vaccines Market, by Vaccine Classification

• 9.1. Introduction
• 9.2. Preventive Vaccines
• 9.3. Therapeutic Vaccines

10. mRNA Vaccines Market, by Application Areas

• 10.1. Introduction
• 10.2. Cardiovascular Disorders
• 10.3. Genetic Disorders
  • 10.3.1. Cystic Fibrosis Treatments
  • 10.3.2. Sickle Cell Disease mRNA Approaches
• 10.4. Infectious Diseases
  • 10.4.1. COVID-19 Vaccines
  • 10.4.2. Influenza mRNA Vaccines
• 10.5. Oncology

11. mRNA Vaccines Market, by End-User

• 11.1. Introduction
• 11.2. Biotechnology Firms
• 11.3. Contract Research Organizations
• 11.4. Pharmaceutical Companies
• 11.5. Research Institutes

12. mRNA Vaccines Market, by Distribution Channel

• 12.1. Introduction
• 12.2. Hospital Pharmacies
• 12.3. Retail Pharmacies

13. Americas mRNA Vaccines Market

• 13.1. Introduction
• 13.2. Argentina
• 13.3. Brazil
• 13.4. Canada
• 13.5. Mexico
• 13.6. United States

14. Asia-Pacific mRNA Vaccines Market

• 14.1. Introduction
• 14.2. Australia
• 14.3. China
• 14.4. India
• 14.5. Indonesia
• 14.6. Japan
• 14.7. Malaysia
• 14.8. Philippines
• 14.9. Singapore
• 14.10. South Korea
• 14.11. Taiwan
• 14.12. Thailand
• 14.13. Vietnam

15. Europe, Middle East & Africa mRNA Vaccines Market

• 15.1. Introduction
• 15.2. Denmark
• 15.3. Egypt
• 15.4. Finland
• 15.5. France
• 15.6. Germany
• 15.7. Israel
• 15.8. Italy
• 15.9. Netherlands
• 15.10. Nigeria
• 15.11. Norway
• 15.12. Poland
• 15.13. Qatar
• 15.14. Russia
• 15.15. Saudi Arabia
• 15.16. South Africa
• 15.17. Spain
• 15.18. Sweden
• 15.19. Switzerland
• 15.20. Turkey
• 15.21. United Arab Emirates
• 15.22. United Kingdom

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Scenario Analysis
  • 16.3.1. Pfizer and BioNTech secure FDA approval for tailored Omicron KP.2 COVID-19 vaccine
  • 16.3.2. BioNTech and CEPI joined hands to enhance Africa's mRNA vaccine landscape with innovative research and local manufacturing
  • 16.3.3. Moderna revealed late-stage trial advancements with progress in the evolution of mRNA vaccine technology
• 16.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Acuitas Therapeutics Inc.
• 2. Alnylam Pharmaceuticals, Inc.
• 3. Arcturus Therapeutics Holdings Inc.
• 4. AstraZeneca PLC
• 5. Bavarian Nordic AS
• 6. BioNTech SE
• 7. Chongqing Zhifei Biological Products Co.,Ltd.
• 8. CureVac N.V.
• 9. Daiichi Sankyo Company, Limited
• 10. Eli Lilly and Company
• 11. Ethris GmbH
• 12. GlaxoSmithKline PLC
• 13. Inovio Pharmaceuticals, Inc.
• 14. Johnson & Johnson Services, Inc.
• 15. Merck & Co., Inc.
• 16. Moderna Inc.
• 17. Novartis AG
• 18. Pfizer Inc.
• 19. Regeneron Pharmaceuticals, Inc.
• 20. Roche Holding AG
• 21. Sanofi S.A.
• 22. Sinovac Biotech Ltd.
• 23. Takeda Pharmaceutical Company Limited
• 24. Thermo Fisher Scientific Inc.
• 25. Vertex Pharmaceuticals Incorporated